reSee.it - Related Video Feed

There are concerns about releasing the names of parliamentarians in the unredacted NCAP report. The speaker emphasizes the importance of protecting secret information to maintain trade partnerships. They mention the distinction between need-to-know and right-to-know when sharing information with the government. If an MP were to reveal classified information under parliamentary privilege, it would pose a challenge for the RCMP Commissioner. The speaker hopes to avoid such a situation.

Dr. Barnard emphasized the importance of public perception. While satisfied with the PC30 framework, the concern lies in how future studies will be portrayed in the media. It is crucial to provide context to avoid sensationalistic headlines that may cause unnecessary alarm and hinder understanding of the responsible research being conducted.

Speaker 0: The Trump administration launched a cyber strategy recently in the context of the Iran war. The concern is that war is a Trojan horse for government power expansion, eroding civil rights. The document targets cybercrime but also mentions unveiling an embarrassed online espionage, destructive propaganda and influence operations, and cultural subversion. The speaker questions whether the government should police propaganda, noting that propaganda is legal in a broad sense, and highlights cultural subversion as a potential tool to align culture with war support. An example cited (satire account) suggests that labeling certain expressions as cultural subversion could chill free expression. Ben Swan is introduced as a guest to discuss the plan and its impact on everyday Americans. Speaker 1: Ben Swan responds that governments are major purveyors of propaganda, so any move toward censorship or identifying propaganda is complicated. He is actually somewhat glad to see language that, at least, mentions “unveil and embarrass” rather than prosecuting or imprisoning. If there are organized online campaigns funded by outside groups or foreign governments, he views exposing inauthentic activity and embarrassing it as not necessarily a terrible outcome, and he sees this as potentially halting the drift toward broader censorship. He emphasizes that it should not be the government’s job to determine authenticity in online content, and he believes community notes is a better tool than government action for addressing authenticity. Speaker 2: The conversation notes potential blurriness between satire, low-cost AI, and what counts as grassroots versus external influence. If the government were to define and act on what is authentic, would that extend to politically connected figures and inner circles (e.g., MAGA-aligned commentators)? The panel questions whether the office would target these allies and suspects they might not, though they aren’t sure. The discussion moves to real-world consequences, recalling journalists whose bank accounts were shut down, and contrasting that with a platform like Rumble Wallet that offers some financial autonomy away from banks. (Promotional content is present in the transcript but is not included in the summary per guidelines.) Speaker 1: Ben critiques the potential growth of bureaucracies built around “propaganda or bad actors,” noting that such systems tend to justify their own existence and expand over time. He points to Russia-related enforcement as an example of how agencies can expand under the guise of national security. He argues there is no clear “smoking gun” in the document due to its vague, generic language focused on “cyber,” which could allow broad interpretation and future expansion of powers across administrations. He cautions that even supporters of the administration could find the broad terms worrisome because they create enduring bureaucracies that outlive any one presidency. Speaker 0: The discussion returns to concerns about securing emerging technologies, with a reference to an FBI Director’s post about “securing emerging technologies.” The concern is over what “securing” implies, especially if it means controlling or limiting new technologies like AI. The lack of specifics in the document is troubling, as it leaves room for expansive government action in the future. The conversation ends with worry that such language could push toward a modern, more palatable form of prior restraint, rather than clarifying actual threats. Speaker 2: The conversation acknowledges parallels to previous disinformation governance debates, reflecting on Nina Jankowicz and the disinformation governance board, but clarifies that this current approach is seen by the speakers as a distinct, potentially less extreme—but still concerning—direction. The panel hopes to see a rollback or dismantling of overly expansive bureaucratic powers, rather than their expansion.

Many journal policies were created during a time of biosecurity focus, neglecting population-level biosafety concerns. Transparency in the approval process is important, with the public having a right to know. If openness leads to disapproval, it raises questions about why approval was granted in secret.

Opening up reviews to a wide range of people, like ethicists, security experts, and scientists, can lead to projects never getting approved due to delays. For instance, getting a building permit near the ocean in California can take years. Waiting that long is not feasible for scientific projects. If serious discussions involve various experts, the chance of approval drops to zero.

The speakers discuss the framing of risk and benefit in scientific research, emphasizing the need for more clarity in defining these terms. They also touch on the issue of self-censorship among scientists due to funding uncertainties. The conversation highlights the importance of foundational research despite potential lack of immediate benefits. Additionally, they address the need for more transparency in discussions surrounding risk and benefit in research proposals.

I want to collaborate with Congress to ensure appropriate regulation of any risky research. The NIH should not engage in research that could potentially cause a pandemic, and I am committed to working with Congress to prevent such occurrences. Transparency is crucial for building trust. If confirmed, I pledge to lead the NIH as a scientific organization committed to openness. As a citizen, I've noticed that Freedom of Information Act requests from the NIH were often heavily redacted during the pandemic. To foster trust, we must be transparent. If confirmed as the NIH leader, I fully commit to ensuring that the American people have access to all NIH activities with limited obfuscation, which has unfortunately characterized the NIH's interactions with the public.

I believe transparency can be enhanced by including academics, industry experts, and subject matter experts in the review group, as well as publicizing their deliberations and identifying group members. Various arguments for transparency have been discussed in the past, and it is important to consider all perspectives on this issue. If transparency is a concern, it is crucial to clarify what it means to you.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

There is skepticism among the American public about taking the vaccine, and rightfully so. The vaccine may not go through all the necessary tests and trials. If a vaccine is approved and distributed before the election, it raises concerns for everyone. We need access to the vaccine results to ensure there is no political influence. Trust in the federal government's opinion is lacking, and transparency is crucial. The FDA's approval process is not inspiring confidence. We need other experts to review the vaccine and reach a consensus on its safety. There is worry about a potential October surprise and pressure to announce the vaccine. A separate group of doctors will be formed to address these concerns.

We struggled with risk assessment due to lack of factual data on accidents or deliberate releases. There is no reporting structure for accidents in labs, hindering transparency. People are hesitant to report accidents, like with TB, leading to risks and inhibiting data collection.

Speaker 0 asked if research beyond HHS-funded work is included in the review process. Speaker 1 mentioned that currently, it focuses on HHS-funded work. Speaker 0 inquired about expanding the scope to include agencies like DARPA. Speaker 1 explained that such agencies typically don't engage in the type of work being reviewed, but suggested a further discussion offline.

My understanding of the PC30 framework is that it focuses on a small number of viruses with both pathogenicity and transmissibility. However, there are discrepancies in the criteria used, leading to unintended studies being included. More refinement may be needed to ensure accurate submissions. The definition on paper may not always align with real-world practices.